All In Biotech

NDA 021782 · Takeda Pharms USA

Rozerem

Ramelteon · Oral · Melatonin Receptor Agonist

Novel

Last checked: Nov 20, 2026Latest source record: Nov 3, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jul 22, 2005

Approved uses

4

Original approval plus efficacy supplements

Registered trials

77

21 Phase 3, 0 recruiting

FAERS reports

7,425

4,086 serious, 808 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2026.

ROZEREM ® is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to six months in duration. The final formal assessments of sleep latency were performed after two days of treatment during the crossover study (elderly only), at five weeks in the six week studies (adults and elderly), and at the end of the six month study (adults and elderly) [see Clinical Studies (14) ] . ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. ( 1 )

Mechanism: Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT 1 and MT 2 receptors and relative selectivity over the MT 3 receptor. The activity of ramelteon at the MT 1 and MT 2 receptors is believed to contribute to its sleep-promoting properties, as these receptors, acted upon by endogenous melatonin, are thought to be involved in the maintenance of the circadian rhythm underlying the normal sleep-wake cycle. Ramelteon has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, noradrenaline,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ROZEREM · RAMELTEON 8MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ramelteon" as an intervention, any sponsor and status, largest first.

All 77 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective927
  • initial insomnia448
  • somnolence422
  • insomnia402
  • middle insomnia390
  • nausea342
  • fatigue291
  • dizziness278
  • headache262
  • off label use249
  • diarrhoea229
  • poor quality sleep219

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200580
2006743
20071,151
2008601
2009115
2010204
2011214
2012201
2013156
2014176
2015348
2016408
2017423
2018380
2019383
2020281
2021311
2022248
2023258
2024248
2025304
2026192

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Mar 19, 2026

    Rozerem, Tablet, 8 mg (NDC 64764-805-10). Product is expected to be available through February 2027.

  • To Be Discontinued · updated Mar 19, 2026

    Rozerem, Tablet, 8 mg (NDC 64764-805-30). Product is expected to be available through June 2027.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rozerem (Ramelteon)

2024 spending

$735K

Beneficiaries

504

1,774 claims

Per beneficiary

$1,459

$11.48 per unit

View as table
YearSpending
2020$3,802,537
2021$1,776,820
2022$1,355,109
2023$1,012,351
2024$735,418

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 118 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.